JLJames Lu

James Lu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


James Lu has a total of 111 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Follow‐Up Bias in Tumor Dynamic Modeling: A Comparison of Classical and Neural‐ODE Approaches

    by David C. Turner, Mark Laurie, Shuhui Li, Huy X. Ngo, Chunze Li, Jin Y. Jin, James Lu, Logan Brooks

    Tumor dynamic models are vital for evaluating oncology treatments and guiding clinical drug development decisions. However, few studies rigorously assess their predictive capabilities, especially when forecasting tumor trajectories from clinical trials with short or inconsistent follow‐up across treatment arms. Poor predictive performance or biases related to follow‐up time could potentially limit the general utility of tumor growth inhibition (TGI) models. This study quantitatively evaluates prediction bias across several established tumor dynamic models, comparing five classical pharmacometric TGI models with the deep learning‐based Tumor Dynamic Neural‐ODE (TDNODE) framework. Using time‐truncated clinical trial data from 3106 patients with non‐small cell lung cancer (NSCLC) across four completed atezolizumab phase III studies, we consistently observed moderate‐to‐high positive bias in the predictions from pharmacometric models, particularly with more limited follow‐up. By examining the structures of these models and comparing them to observed data, we highlight how the assumed kinetic patterns potentially lead to biased parameter estimation and systemic overestimation of tumor size when applied to immature datasets. In contrast, the TDNODE framework, using deep learning, demonstrated promising early results, exhibiting improved predictive performance in the same evaluations. These findings underscore the critical need to address prediction bias in tumor dynamic modeling with immature data and to consider alternative approaches to established paradigms for certain drug development applications. This study also generally demonstrates the potential of novel methods, such as deep learning, to potentially enhance the reliability of tumor dynamics modeling, especially in challenging early‐phase clinical decision‐making scenarios.


  • Open Access

    Building Hybrid Pharmacometric‐Machine Learning Models in Oncology Drug Development: Current State and Recommendations

    by Anna Fochesato, Logan Brooks, Omid Bazgir, Philippe B. Pierrillas, Candice Jamois, James Lu, Francois Mercier

    Classic and hybrid pharmacometric‐machine learning models (hPMxML) are gaining momentum for applications in clinical drug development and precision medicine, especially within the oncology therapeutic area. However, standardized workflows are needed to ensure transparency, rigor, and effective communication for broader adoption. In this tutorial, we review pharmacometric (PMx) and machine learning (ML) reporting standards and evaluate them against hPMxML works in oncology contexts as a motivational example to identify current deficiencies and propose mitigation strategies for future efforts. The revealed gaps include insufficient benchmarking, absence of error propagation, feature stability assessments, and ablation studies, limited focus on external validation and final parametrization, and discrepancies between the performance metrics chosen and the original clinical questions. To address these, we propose a checklist for hPMxML model development and reporting, consisting of steps for estimand definition, data curation, covariate selection, hyperparameter tuning, convergence assessment, model explainability, diagnostics, uncertainty quantification, validation and verification with sensitivity analyses. This standardized approach is expected to enhance the reliability and reproducibility of hPMxML outputs, enabling their confident application in oncology clinical drug development, while fostering trust among all stakeholders.


  • Open Access

    Shap‐Cov: An Explainable Machine Learning Based Workflow for Rapid Covariate Identification in Population Modeling

    by Logan Brooks, Rashed Harun, Jin Y. Jin, James Lu

    Covariate identification in population pharmacokinetic/pharmacodynamic (popPK/PD) modeling is a key component in model development that is often prone to bias, time‐consuming, and even intractable when too many covariates or complicated models are being considered. Early work leveraging machine learning (ML) for covariate screening has shown promising results over traditional methods. In this work, we expand this effort by integrating explainable machine learning facilitated by Shapley Additive Explanations (SHAP) analysis and covariate uncertainty quantification as well as a formal framework for establishing statistical significance of covariate relationships. Finally, we have packaged the proposed methodology into a flexible set of functions (shap‐cov) to support popPK/PD modeling covariate identification.


  • Open Access

    AI‐Driven Applications in Clinical Pharmacology and Translational Science: Insights From the ASCPT 2024 AI Preconference

    by Mohamed H. Shahin, Prashant Desai, Nadia Terranova, Yuanfang Guan, Tomáš Helikar, Sebastian Lobentanzer, Qi Liu, James Lu, Subha Madhavan, Gary Mo, et al.

    Artificial intelligence (AI) is driving innovation in clinical pharmacology and translational science with tools to advance drug development, clinical trials, and patient care. This review summarizes the key takeaways from the AI preconference at the American Society for Clinical Pharmacology and Therapeutics (ASCPT) 2024 Annual Meeting in Colorado Springs, where experts from academia, industry, and regulatory bodies discussed how AI is streamlining drug discovery, dosing strategies, outcome assessment, and patient care. The theme of the preconference was centered around how AI can empower clinical pharmacologists and translational researchers to make informed decisions and translate research findings into practice. The preconference also looked at the impact of large language models in biomedical research and how these tools are democratizing data analysis and empowering researchers. The application of explainable AI in predicting drug efficacy and safety, and the ethical considerations that should be applied when integrating AI into clinical and biomedical research were also touched upon. By sharing these diverse perspectives and real‐world examples, this review shows how AI can be used in clinical pharmacology and translational science to bring efficiency and accelerate drug discovery and development to address patients' unmet clinical needs.


  • Top Cited Papers
    Open Access

    Large Language Models and Their Applications in Drug Discovery and Development: A Primer

    by James Lu, Keunwoo Choi, Maksim Eremeev, Jogarao Gobburu, Srijib Goswami, Qi Liu, Gary Mo, Cynthia J. Musante, Mohamed H. Shahin

    Large language models (LLMs) have emerged as powerful tools in many fields, including clinical pharmacology and translational medicine. This paper aims to provide a comprehensive primer on the applications of LLMs to these disciplines. We will explore the fundamental concepts of LLMs, their potential applications in drug discovery and development processes ranging from facilitating target identification to aiding preclinical research and clinical trial analysis, and practical use cases such as assisting with medical writing and accelerating analytical workflows in quantitative clinical pharmacology. By the end of this paper, clinical pharmacologists and translational scientists will have a clearer understanding of how to leverage LLMs to enhance their research and development efforts.


  • Open Access

    Integrating real‐world data and machine learning: A framework to assess covariate importance in real‐world use of alternative intravenous dosing regimens for atezolizumab

    by Bianca Vora, Ashutosh Jindal, Erick Velasquez, James Lu, Benjamin Wu

    The increase in the availability of real‐world data (RWD), in combination with advances in machine learning (ML) methods, provides a unique opportunity for the integration of the two to explore complex clinical pharmacology questions. Here we present a recently developed RWD/ML framework that utilizes ML algorithms to understand the influence and importance of various covariates on the use of a given dose and schedule for drugs that have multiple approved dosing regimens. To demonstrate the application of this framework, we present atezolizumab as a use case on account of its three approved alternative intravenous (IV) dosing regimens. As expected, the real‐world use of atezolizumab has generally been increasing since 2016 for the 1200 mg every 3 weeks regimen and since 2019 for the 1680 mg every 4 weeks regimen. Out of the ML algorithms evaluated, XGBoost performed the best, as measured by the area under the precision–recall curve, with an emphasis on the under‐sampled class given the imbalance in the data. The importance of features was measured by Shapley Additive exPlanations (SHAP) values and showed metastatic breast cancer and use of protein‐bound paclitaxel as the most correlated with the use of 840 mg every 2 weeks. Although patient usage data for alternative IV dosing regimens are still maturing, these analyses provide initial insights on the use of atezolizumab and set up a framework for the re‐analysis of atezolizumab (at a future data cut) as well as application to other molecules with approved alternative dosing regimens.


  • Open Access

    Predicting overall survival from tumor dynamics metrics using parametric statistical and machine learning models: application to patients with RET-altered solid tumors

    by Erick Velasquez, Nastya Kassir, Sravanthi Cheeti, Denison Kuruvilla, Rucha Sane, Steve Dang, Dale Miles, James Lu

    In oncology drug development, tumor dynamics modeling is widely applied to predict patients' overall survival (OS) via parametric models. However, the current modeling paradigm, which assumes a disease-specific link between tumor dynamics and survival, has its limitations. This is particularly evident in drug development scenarios where the clinical trial under consideration contains patients with tumor types for which there is little to no prior institutional data. In this work, we propose the use of a pan-indication solid tumor machine learning (ML) approach whereby all three tumor metrics (tumor shrinkage rate, tumor regrowth rate and time to tumor growth) are simultaneously used to predict patients' OS in a tumor type independent manner. We demonstrate the utility of this approach in a clinical trial of cancer patients treated with the tyrosine kinase inhibitor, pralsetinib. We compared the parametric and ML models and the results showed that the proposed ML approach is able to adequately predict patient OS across RET-altered solid tumors, including non-small cell lung cancer, medullary thyroid cancer as well as other solid tumors. While the findings of this study are promising, further research is needed for evaluating the generalizability of the ML model to other solid tumor types.


  • Open Access

    Population pharmacokinetics and CD20 binding dynamics for mosunetuzumab in relapsed/refractory B‐cell non‐Hodgkin lymphoma

    by Brendan Bender, Chi‐Chung Li, Mathilde Marchand, David C. Turner, Feifei Li, Shweta Vadhavkar, Bei Wang, Rong Deng, James Lu, Jin Jin, et al.

    Mosunetuzumab (Mosun) is a CD20xCD3 T‐cell engaging bispecific antibody that redirects T cells to eliminate malignant B cells. The approved step‐up dose regimen of 1/2/60/30 mg IV is designed to mitigate cytokine release syndrome (CRS) and maximize efficacy in early cycles. A population pharmacokinetic (popPK) model was developed from 439 patients with relapsed/refractory B‐Cell Non‐Hodgkin lymphoma receiving Mosun IV monotherapy, including fixed dosing (0.05–2.8 mg IV every 3 weeks (q3w)) and Cycle 1 step‐up dosing groups (0.4/1/2.8–1/2/60/30 mg IV q3w). Prior to Mosun treatment, ~50% of patients had residual levels of anti‐CD20 drugs (e.g., rituximab or obinutuzumab) from prior treatment. CD20 receptor binding dynamics and rituximab/obinutuzumab PK were incorporated into the model to calculate the Mosun CD20 receptor occupancy percentage (RO%) over time. A two‐compartment model with time‐dependent clearance (CL) best described the data. The typical patient had an initial CL of 1.08 L/day, transitioning to a steady‐state CL of 0.584 L/day. Statistically relevant covariates on PK parameters included body weight, albumin, sex, tumor burden, and baseline anti‐CD20 drug concentration; no covariate was found to have a clinically relevant impact on exposure at the approved dose. Mosun CD20 RO% was highly variable, attributed to the large variability in residual baseline anti‐CD20 drug concentration (median = 10 μg/mL). The 60 mg loading doses increased Mosun CD20 RO% in Cycle 1, providing efficacious exposures in the presence of the competing anti‐CD20 drugs. PopPK model simulations, investigating Mosun dose delays, informed treatment resumption protocols to ensure CRS mitigation.


  • Open Access

    Integration of Graph Neural Network and Neural-ODEs for Tumor Dynamic Prediction

    by Omid Bazgir, Zichen Wang, Ji Won Park, Marc Hafner, James Lu

    In anti-cancer drug development, a major scientific challenge is disentangling the complex relationships between high-dimensional genomics data from patient tumor samples, the corresponding tumor's organ of origin, the drug targets associated with given treatments and the resulting treatment response. Furthermore, to realize the aspirations of precision medicine in identifying and adjusting treatments for patients depending on the therapeutic response, there is a need for building tumor dynamic models that can integrate both longitudinal tumor size as well as multimodal, high-content data. In this work, we take a step towards enhancing personalized tumor dynamic predictions by proposing a heterogeneous graph encoder that utilizes a bipartite Graph Convolutional Neural network (GCN) combined with Neural Ordinary Differential Equations (Neural-ODEs). We applied the methodology to a large collection of patient-derived xenograft (PDX) data, spanning a wide variety of treatments (as well as their combinations) on tumors that originated from a number of different organs. We first show that the methodology is able to discover a tumor dynamic model that significantly improves upon an empirical model which is in current use. Additionally, we show that the graph encoder is able to effectively utilize multimodal data to enhance tumor predictions. Our findings indicate that the methodology holds significant promise and offers potential applications in pre-clinical settings.